AACR Names Dr. Chi Van Dang as Editor-in-Chief of Cancer Research Journal


PHILADELPHIA — The American Associa​tion for Cancer Research (AACR) is pleased to announce the appointment of Chi Van Dang, MD, PhD, as editor-in-chief of its Cancer Research journal. Published under different titles in its early years, Cancer Research was the first English-language journal to be published in the field of oncology and is arguably the most influential cancer research journal in the world today.

Dang is the scientific director of the Ludwig Institute for Cancer Research, an international, not-for-profit organization of distinguished scientists dedicated to preventing and controlling cancer.  He is also a professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia. Dang officially began his term as editor-in-chief of Cancer Research on Jan. 1, and his inaugural editorial can be found here.

“Dr. Dang is a prominent and highly regarded physician-scientist, and the American Association for Cancer Research is thrilled to welcome him in his role as editor-in-chief of Cancer Research,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “His extensive expertise as a cancer scientist and hematologic oncologist and his 20 years of clinical academic leadership experience at preeminent research institutions will further the success and impact of this important journal and accelerate the pace of progress against cancer.”

Cancer Research publishes original studies, reviews, and opinion pieces spanning the spectrum of cancer research. This semi-monthly journal has a stringent peer review process, accepting only those studies that are novel, timely, and of broad significance in the field.

“I am delighted to assume responsibility for this influential journal at a time when cancer research is providing hope that allows us to begin to use the word ‘cure’ without trepidation,” Dang said. “Together with the newly assembled editorial board, I look forward to promoting major scientific findings that embrace innovative research paradigms and team science.”

Dang is a pioneer in biomedical cancer research. His lab was the first to report a link between an oncogene and altered cancer cell metabolism through the discovery that the oncogenic transcription factor MYC plays a pivotal role in the re-programming of fuel utilization in cancer cells, making cancers addicted to certain fuel sources. Research in the Dang laboratory currently focuses on exploiting metabolic vulnerabilities of cancer cells for therapeutic benefit.

Dang received his bachelor’s degree in chemistry from the University of Michigan, Ann Arbor; PhD in chemistry from Georgetown University, Washington, D.C.; and his MD from the Johns Hopkins University School of Medicine, Baltimore. He has published two books, numerous book chapters, and more than 250 scientific articles. Dang is also the recipient of numerous honors. He was appointed to the Blue Ribbon Panel of former Vice President Joe Biden’s National Cancer Moonshot Initiative, is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Medicine (Institute of Medicine), and chair of the National Cancer Institute’s Board of Scientific Advisors.